Dr. Leland Gershell
Recent Articles
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease 10/09/2025
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
Biotech Discovers Breakthrough DMD Therapy Opportunity 09/26/2025
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc.
Biopharma Shares Efficacy Data at AUA Meeting 05/01/2025
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.
Analyst's Target Price for Biotech Massively Higher Than Current Price 07/22/2024
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price.
